Back to discover
Disease

Anaplastic large cell lymphoma

Late-stage therapeutic development
Also known as ALCL, CD30 Positive anaplastic large cell lymphoma, CD30 positive anaplastic large cell lymphoma, Ki-1 lymphoma+5 more

ALCL, CD30 Positive anaplastic large cell lymphoma, CD30 positive anaplastic large cell lymphoma, Ki-1 lymphoma, Ki-1 positive anaplastic large cell lymphoma, Ki-1+ ALCL, Ki-1+ anaplastic large cell lymphoma, primary systemic ALCL, sACL.

20
Clinical trials
10
Associated genes
3
Related proteins
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q3 2027.
Upcoming Milestones
Clinical Milestones8View
Results expected 4
Recently completed 4
Activity timeline8

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Crizotinibapproved

Original application approval — Xalkori as monotherapy is indicated for: The first line treatment of adults with anaplas… (2012)

Clinical trials

14 sponsors · 0 new · 2 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
4
Late-stage
6
Completed
Late-stage studies

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients With Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Phase 3 · Recruiting · Eastern Cooperative Oncology Group

Using a Modified ALCL99 Regimen for Chinese Children With Newly Diagnosed High-risk Anapestic Large Cell Lymphoma

Phase 3 · Active, not recruiting · Children's Cancer Group, China

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Phase 2/3 · Recruiting · Cancer Research UK

A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Phase 3 · Completed · Millennium Pharmaceuticals, Inc.
Recruiting

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients With Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Phase 3 · Recruiting · Eastern Cooperative Oncology Group

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Phase 2/3 · Recruiting · Cancer Research UK

NYMC623: A Comprehensive Risk-adapted Chemommunotherapy Protocol of Emerging Immunotherapies for Relapsed/Refractory Alk+ Anaplastic Large Cell Lymphoma (ACCELERATE)

Phase 2 · Recruiting · New York Medical College
Recently completed

A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)

Phase 2 · Completed · University of Milano Bicocca

Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Phase 1/2 · Completed · M.D. Anderson Cancer Center

Phase II Study of Vinorelbine for Children with Recurrent Anaplastic Large Cell Lymphoma

Phase 2 · Completed · Children's Cancer Group, China

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study

Phase 1/2 · Completed · Fondazione Italiana Linfomi - ETS

Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")

Phase 2 · Completed · European Organisation for Research and Treatment of Cancer - EORTC

A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Phase 3 · Completed · Millennium Pharmaceuticals, Inc.

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2012emaOriginal application approval — Crizotinib· Xalkori as monotherapy is indicated for: The first line treatment of adults with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) The treatment of adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) The treatment of adults with ROS1 positive advanced non small cell lung cancer (NSCLC) The treatment of paediatric patients (age 1 to <18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) The treatment of paediatric patients (age 1 to <18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK) positive unresectable inflammatory myofibroblastic tumour (IMT) source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

10 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

TNFRSF80.53ALK0.51NPM10.41TPM30.38TFG0.38ATIC0.37MSN0.28JUNB0.11SLAMF80.08PPID0.07

Disease biology

3 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Tumor necrosis factor receptor superfamily member 8via TNFRSF80.53ALK tyrosine kinase receptorvia ALK0.51Nucleophosminvia NPM10.41

Reference

Authoritative identity, definition & identifiers.

Synonyms

ALCL, CD30 Positive anaplastic large cell lymphoma, CD30 positive anaplastic large cell lymphoma, Ki-1 lymphoma, Ki-1 positive anaplastic large cell lymphoma, Ki-1+ ALCL, Ki-1+ anaplastic large cell lymphoma, primary systemic ALCL, sACL

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.